Showing 981-990 of 1184 results for "".
Build Your Dream Team
https://modernod.com/topics/business/build-your-dream-team/38033/Tips for finding the right individuals to add to your office staff.Get Familiar With Infectious Retinitis
https://modernod.com/topics/retina/get-familiar-with-infectious-retinitis/37981/Prompt diagnosis is key for successful management of this rare yet potentially devastating condition.Imaging and Patient Education
https://modernod.com/topics/ocular-surface/imaging-and-patient-education/39181/Images can be used to educate patients and increase adherence to therapy.Anatomically Narrow Angles: How to Deal
https://modernod.com/topics/glaucoma/anatomically-narrow-angles-how-to-deal/39171/Review these tips for identification and updates on treatment.The High-Performance Vision Machine
https://modernod.com/topics/cataractrefractive-surgery/the-high-performance-vision-machine/39154/Ophthalmologists and optometrists are the pit crew that can optimize long-lasting, high-quality visual performance.Endoscopic Cyclophotocoagulation for Glaucoma
https://modernod.com/mod-issues/2021-mar/endoscopic-cyclophotocoagulation-for-glaucoma/39121/This laser procedure can be an option for patients who want to reduce dependence on drops.- Visiox Pharma Appoints Ryan S. Bleeks as Chief Executive Officerhttps://modernod.com/news/visiox-pharma-appoints-ryan-s-bleeks-as-chief-executive-officer/2480872/Visiox Pharma announced the appointment of Ryan S. Bleeks as Chief Executive Officer. "We are excited to have Ryan join Visiox at this critical time for the organization," said Michael Derby, Visiox's Founding Investor and Executive Chairman. "His
- RetinAI Joins Ryan Initiative for Macular Research AMD Consortiumhttps://modernod.com/news/retinai-joins-ryan-initiative-for-macular-research-amd-consortium/2481987/RetinAI Medical announced that they are now joining the Ryan Initiative for Macular Research (RIMR) Age-related Macular Degeneration (AMD) Imaging Consortium, a non-profit group of physicians, researchers, and industry partners working together to define optimal biomarkers and endpoints in AMD.</
- OD-OS Achieves Revocation of Iridex MicroPulse Patenthttps://modernod.com/news/od-os-achieves-revocation-of-iridex-micropulse-patent/2480020/OD-OS has achieved the revocation of the MicroPulse Patent (Patent no EP1856774) by Iridex Corporation in oral proceedings at the European Patent office held last Friday in Munich, Germany according to an OD-OS news release. With its successful opposition, OD-OS has cleared the path to man
- OD-OD Introduces a New Learning App for Retinal Laser Treatmenthttps://modernod.com/news/od-od-introduces-a-new-learning-app-for-retinal-laser-treatment/2479529/To address growing demand for interactive learning technology, OD-OS has developed a tool for implementing a better approach to retinal laser treatment: The Navigate App. Navigate is a free, interactive tool designed to support residents and team education—both onsite and online. The platf